Yes, both oncogenes and tumor suppressor genes can be targeted for cancer therapy. For example, drugs like imatinib (Gleevec) specifically inhibit the BCR-ABL fusion protein, an oncogene product in chronic myeloid leukemia. Similarly, restoring the function of mutated tumor suppressor genes or mimicking their activity is a promising area of research, although it is technically more challenging.
